Sort
82,697 grants matching “vaccine development”
Improving the Outcome of Patients with Chronic Myeloid Leukemia Through Medi
$1,390,873Jorge E Cortes · University Of Tx Md Anderson Can Ctr · P01 · FY2010 · CA
Active Immune Therapy and HAART for HIV-1 Infection
$1,390,708University Of Pennsylvania · P01 · FY2001 · AI
Therapeutic Vaccination for HIV Using VEE Vectors
$1,390,608University Of North Carolina Chapel Hill · P01 · FY2002 · AI
Early in vivo Expressed Antigens and their Role in Virulence, Immune Response, and Vaccines for Coccidioidomycosis
$1,390,215Paul Stephen Keim · Northern Arizona University · U19 · FY2023 · AI
Host Immunity Against Bacteria
$1,389,789Sandip Datta · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI
A Randomized Controlled Trial of Prophylaxis with Direct-acting Antivirals for Kidney Transplantation from Hepatitis C virus-infected donor to Uninfected Recipients (PREVENT-HCV)
$1,389,503Christine Marie Durand · Johns Hopkins University · U01 · FY2023 · AI
Heat Shock Protein and Thermal Therapy of Cancer
$1,389,197Roswell Park Cancer Institute Corp · P01 · FY2005 · CA
Adjuvant Development Program in the context of vaccines to protect against Y. pestis and Shigella.
$1,388,963Robert Ernst · University Of Maryland Baltimore · N01 · FY2022 · AI
HIV VACCINE CLINICAL TRIALS UNIT
$1,388,773University Of Rochester · U01 · FY2003 · AI
San Francisco Bay Clinical Trials Unit
$1,388,627Susan Buchbinder · Public Health Foundation Enterprises · UM1 · FY2016 · AI
Molecular Analysis of Tuberculosis Immunity
$1,388,602William Robert Jacobs · Albert Einstein College Of Medicine · P01 · FY2007 · AI
DNA AND PROTEIN IMMUNOGENS FOR SIV/HIV VACCINES
$1,388,337Emory University · P01 · FY2000 · AI
A Randomized Controlled Trial of Prophylaxis with Direct-acting Antivirals for Kidney Transplantation from Hepatitis C virus-infected donor to Uninfected Recipients (PREVENT-HCV)
$1,388,200Christine Marie Durand · Johns Hopkins University · U01 · FY2024 · AI
MACROPHAGES, DENDRITIC CELLS AND PATHOGENS
$1,388,080Weill Medical College Of Cornell Univ · P01 · FY2005 · AI
Malaria Drug Resistance and Disease Virulence
$1,388,069Thomas E Wellems · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure
$1,387,573Sharon Riddler · University Of Pittsburgh At Pittsburgh · U01 · FY2019 · AI
Non-Viral Pandemic Influenza Vaccine Development
$1,387,125Gary Fujii · Molecular Express, Inc. · U01 · FY2007 · AI
Johns Hopkins University-Guangxi, China Clinical Trials Unit
$1,386,714Jay B Jackson · Johns Hopkins University · U01 · FY2010 · AI
CIPRA-SA: Safeguard the household: comprehensive AIDS research: Extension
$1,386,629James Alasdair McIntyre · Wits Health Consortium (Pty), Ltd · U19 · FY2010 · AI
CAPRISA Clinical Trials Unit for AIDS/Tuberculosis Prevention and Treatment
$1,386,485Quarraisha Abdool Karim · Centre/Aids Programme/Res/South Africa · UM1 · FY2016 · AI
EMORY/ATLANTA CENTER FOR AIDS RESEARCH(CFAR)
$1,386,447Emory University · P30 · FY2002 · AI
Preclinical Studies and Mucosal Responses
$1,386,249Rama Rao Amara · Geovax, Inc. · U19 · FY2011 · AI
Data Analysis and Management Core
$1,385,561Raphael Gottardo · Seattle Children'S Hospital · U19 · FY2020 · AI
Data Analysis and Management Core
$1,385,558Raphael Gottardo · Seattle Children'S Hospital · U19 · FY2021 · AI
Tfh and B cells in HIV/SIV pathogenesis and vaccination
$1,385,242Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI